T1D Exchange Research in the Spotlight at ADA
From June 25-29, 2021, the most brilliant minds in diabetes research gathered (virtually) for the American Diabetes Association’s (ADA) 81st…
Bigfoot Unity Cleared and Ready to Step Out: Interview with Jeffrey Brewer, CEO, Bigfoot Biomedical
On May 10, 2021 Bigfoot Biomedical Inc. received FDA Clearance for its Bigfoot Unity Diabetes Management System. Jeffrey Brewer is…
T1D Exchange Announces Two New Appointments to its Board of Directors
T1D Exchange Announces Two New Appointments to its Board of Directors April 14, 2021 T1D Exchange announced today the appointments of Gary A. Puckrein, Ph.D. and Phillip Cagnassola to its Board…
New T1D Equity Framework Partnership with Medtronic Inc.
Vertex Pharmaceuticals Pursues Investigational Cell Therapies for Type 1 Diabetes
In the fall of 2019, Vertex Pharmaceuticals Incorporated acquired Semma Therapeutics for $950 million. Founded by Douglas Melton, Ph.D. and…
Screening for T1D: Using the New T1Detect Kit
Screening for type 1 diabetes is now easier than ever before. Although screening has been available for many years, now…
Chatting with Dexcom CEO About the New G7, the Sampling Program, and the Patient Voice
There are approximately 900,000 people across the globe wearing a Dexcom continuous glucose monitor (CGM) today. “Up from 600,000 at…
Glucose Revival Founder Kris Maynard Makes T1D Life Easier
Have you ever been going about your daily routine (either exercising, traveling, or just spending an evening with friends or…
Racial Inequities Among People with Type 1 Diabetes and COVID-19
T1D Exchange is honored to have our recent study results examining racial inequities among people with type 1 diabetes and COVID-19 included in two major publications. Structural and systemic…
2020 Highlights: COVID-19 Guidance, Daily Hurdles of T1D and Mental Health
At T1D Exchange, we strive to post articles that connect the T1D community. Today we’re sharing the three most viewed…
